Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
89%(8 trials)

Phase Distribution

Ph phase_4
1
11%
Ph phase_3
2
22%
Ph phase_2
5
56%

Phase Distribution

0

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
2(25.0%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (62.5%)
Phase 32 (25.0%)
Phase 41 (12.5%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completed

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

NCT01287988
completedphase_4

Assessment of Patients Treated With JETREA® for Vitreomacular Traction

NCT02035748
completedphase_3

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

NCT01429441
completedphase_3

A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion

NCT01889251
completedphase_2

A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)

NCT00435539
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01287988

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

Completed
NCT02035748Phase 4

Assessment of Patients Treated With JETREA® for Vitreomacular Traction

Completed
NCT01429441Phase 3

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Completed
NCT01889251Phase 3

A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion

Completed
NCT00435539Phase 2

A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)

Completed
NCT00412451Phase 2

A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)

Completed
NCT00986362Phase 2

Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy

Completed
NCT00913744Phase 2

Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

Completed
NCT01159665Phase 2

The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9